Men | Women | |||
---|---|---|---|---|
HR | 95% CI | HR | 95% CI | |
Age ≥ 80 years | 2.15# | (1.70–2.72) | 3.33# | (2.38–4.65) |
IADL < 24 pts | 2.95# | (2.30–3.79) | 1.87# | (1.33–2.63) |
MNA < 12 pts | 2.03# | (1.63–2.52) | 2.00# | (1.48–2.70) |
Negative inflammatory subgroup | Ref. | Ref. | ||
Single positive inflammatory subgroup | 1.34* | (1.02–1.77) | 1.44* | (1.04–1.99) |
Double positive inflammatory subgroup | 2.36# | (1.77–3.14) | 2.99# | (2.09–4.27) |
Metabolic syndrome | NS | NS | ||
Visceral obesity | 0.79* | (0.63–0.98) | 0.49# | (0.35–0.69) |
Normal glucose control | Ref. | Ref. | ||
Prediabetes | NS | NS | ||
Diabetes mellitus | NS | NS | ||
Hypertriglyceridemia | NS | NS | ||
Hypercholesterolemia | NS | NS | ||
Coronary artery disease | NS | NS | ||
Heart failure | NS | 1.65# | (1.24–2.20) | |
Cancer survivors | NS | NS | ||
eGFR < 45 ml/min/1.73m2 | 1.83# | (1.36–2.47) | 1.76* | (1.28–2.42) |
Albumin ≥ 40 mg/dL | 0.73** | (0.57–0.92) | NS |